Spago Nanomedical

Spago Nanomedical is a Lund-based clinical-stage nanomedicine company developing two platforms: Tumorad — a targeted radionuclide therapy that accumulates in solid tumours for precise internal radiation — and SpagoPix, an MRI contrast agent. The Tumorad platform exploits the EPR effect to selectively deliver radiation to tumours while sparing healthy tissue. Listed on Nasdaq First North, Spago has approximately 15 employees and is in Phase I/II clinical development.